Optimization of orally bioavailable alkyl amine renin inhibitors
- PMID: 19959358
- DOI: 10.1016/j.bmcl.2009.11.066
Optimization of orally bioavailable alkyl amine renin inhibitors
Abstract
Structure-guided drug design led to new alkylamine renin inhibitors with improved in vitro and in vivo potency. Lead compound 21a, has an IC(50) of 0.83nM for the inhibition of human renin in plasma (PRA). Oral administration of 21a at 10mg/kg resulted in >20h reduction of blood pressure in a double transgenic rat model of hypertension.
Copyright 2009 Elsevier Ltd. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information
Research Materials